|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Collaboration revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Acquired in-process research and development | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Other (expense) income, net: | |||||
| Interest income | |||||
| Non-cash interest expense for the sale of future royalties | |||||
| Other income (expense), net | |||||
| Total other (expense) income, net | |||||
| Loss before income taxes | |||||
| (Provision) benefit for income taxes | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Unrealized (loss) gain on available for sale securities | |||||
| Comprehensive loss | |||||
| Net loss per common share: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted-average number of shares outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...